ArticleBMJ open2019

Oral insulin therapy for primary prevention of type 1 diabetes in infants with high genetic risk: the GPPAD-POInT (global platform for the prevention of autoimmune diabetes primary oral insulin trial) study protocol.

Anette-Gabriele Ziegler et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.